$0.00
$30.00
bear $0.00
base $0.00
bull $30.00
margin of safety $6.00
market price* $393.44
Business condition attached to the margin of safety
Positive owner earnings after counting stock compensation as a cost, meaning operating cash flow (before working-capital swings) less stock compensation and maintenance capex is above zero for a full year.
Natera runs blood-based genetic tests in three areas: cancer (Signatera, which detects leftover or returning cancer from circulating tumor DNA), women's health (Panorama and Horizon, prenatal and carrier screening) and organ health (Prospera, transplant rejection). Revenue was $2.31 billion in 2025, up 36% from $1.70 billion in 2024 and $1.08 billion in 2023. Test volume grew to about 3.34 million reports in 2025 from 2.93 million, and cancer tests grew faster, from about 528,000 to about 801,000. Roughly 98% of revenue is booked in the United States, and no customer exceeds 10% of revenue. Signatera is covered by Medicare for several uses and holds a special Medicare pricing status. How we measure it. We count what the business earns for its owners: operating cash flow, with swings in receivables and payables removed, minus stock-based pay (a real cost paid in shares), minus the part of capital spending needed just to stay in place. On that basis Natera has lost money every year we measured: about $(5.54) per share in 2022, $(3.48) in 2023, $(1.24) in 2024 and $(1.77) in 2025. Operating cash flow turned positive in 2024 ($136 million) and 2025 ($215 million), but stock compensation of $354 million in 2025 more than wipes that out. Owner earnings were about $(242) million in 2025. The improvement from 2022 through 2024 was real, but 2025 went backwards because research spending rose 54% and selling and administrative costs rose 40% while revenue rose 36%. We did not put the $1.1 billion of cash on the balance sheet into the value, because we value the earnings stream, not the bank balance; the company also carried about $80 million drawn on a credit line at year-end. Cash and the funding it provides matter to whether the company can keep operating, but they do not change what the operating business is earning for its owners. Base case, $0 per share. Growth in tests and price is real, but growth in the bag needs a contract, a backlog or a long steady record of small steps. Natera's pace of adding cancer patients depends on new physician adoption and insurance decisions, so we did not credit it. On what has already been shown, each extra dollar of revenue over 2023 to 2025 added only about 13 cents of owner earnings (owner earnings improved by about $158 million on $1.22 billion more revenue). Even with revenue growing 15%, 12%, 10%, 8% and 6% over five years at that rate, owner earnings would still be negative. So the business as it demonstrably operates today is worth nothing to owners, and we do not credit cost cuts or margin gains that have not yet appeared. Bear case, $0 per share. Costs keep pace with revenue, stock compensation stays above operating cash flow, and the company must issue more shares or borrow to fund the losses. The disclosed risks include continued net losses (accumulated deficit of $2.8 billion), reliance on insurer coverage for Signatera, Panorama and Horizon, and competition from BGI, BillionToOne, Fulgent, Illumina, Labcorp and others. We also note the December 2025 Foresight Diagnostics acquisition and a China license for Signatera with BGI Genomics that runs to February 2029; neither adds value in our cases. Bull case, about $30 per share. Natera repeats what it achieved in 2024, when owner earnings improved by roughly 40 cents per extra dollar of revenue, and revenue growth slows from 15% a year to 2% by year nine. Owner earnings turn positive in year two and reach about $540 million a year by year ten. We then hold that level flat for a further ten years and assume nothing after that. This is the most favourable outcome we can build from the record of the business's own operating leverage, and 2025 shows it does not happen automatically. What would make this wrong. If stock compensation falls sharply as a share of revenue, or the business converts more of each new revenue dollar into cash than the 13 cents seen so far, the base case would be positive and the estimate would be revisited. The margin-of-safety price of $6 reflects a wide gap between a zero downside and a much higher upside, and applies only once the business has shown positive owner earnings for a full year. We could not reconcile why 2025 accounts receivable showed a decrease while revenue grew 36%; we treated it as reported, and it changes owner earnings by only a few million dollars.